SciSparc Business Summary

SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company that operates a dual-track revenue model combining long-term drug development with immediate commercial sales. The company generates revenue through two primary business segments: the development of high-margin cannabinoid-based pharmaceuticals and the direct-to-consumer online sale of hemp-based nutraceuticals, including oils and topicals, primarily via Amazon. SciSparc’s clinical pipeline focuses on central nervous system disorders, utilizing its proprietary CannAmide™ and SCI-110 platforms to treat conditions such as Tourette Syndrome and Alzheimer's-related agitation. In early 2026, the company expanded its portfolio into the medical device sector by acquiring intellectual property for endoscopic systems and gastroesophageal reflux disease (GERD) treatments. Within the competitive landscape, SciSparc contends with specialty pharma and biotech firms such as Medexus Pharmaceuticals, Phio Pharmaceuticals, Novogen, and Biofrontera, positioning itself as a nano-cap player that mitigates R&D risk through diversified consumer health revenue and strategic IP acquisitions. The leadership team is anchored by CEO and CFO Oz Adler, a CPA with extensive financial and managerial experience from his tenure at Ernst & Young (Kost Forer Gabbay & Kasierer). Technical operations are led by CTO Dr. Adi Zuloff-Shani, who brings over 20 years of R&D expertise and previously served as VP of Development at Macrocure Ltd. The executive ranks were further strengthened in late 2025 with the appointment of Amitay Weiss as President and Itschak Shrem as Chairman of the Board. Shrem is a prominent figure in the Israeli venture capital ecosystem, having founded Pitango Venture Capital (formerly Polaris) and Dovrat Shrem Ltd. The board also includes notable members such as Alon Dayan, CEO of Virtual Crypto Technologies, and Amnon Ben Shay. This leadership group oversees a lean operational structure focused on advancing clinical trials while navigating Nasdaq compliance through strategic capital raises and portfolio diversification.